Longitude Capital Partners III, LLC

Insider Reports History

Location
Menlo Park, CA
Signature
Longitude Venture Partners III, L.P.; By /s/ Patrick G. Enright, Managing Member of the general partner
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Longitude Capital Partners III, LLC:

Company Role Class Num Shares Value Price $ Report Date Ownership
Talaris Therapeutics, Inc. 10%+ Owner Common Stock 3,220,775 $54,720,967 $16.99 11 May 2021 By Longitude Venture Partners III, L.P.
Inozyme Pharma, Inc. 10%+ Owner Common Stock 4,174,379 $14,902,533 $3.57 19 Apr 2022 By Longitude Venture Partners III, L.P.
Sierra Oncology, Inc. 10%+ Owner Common Stock 8,015 $440,825 $55.00 27 Apr 2022 Indirect
Talaris Therapeutics, Inc. 10%+ Owner Series A-1 Preferred Stock 0 11 May 2021 By Longitude Venture Partners III, L.P.
Talaris Therapeutics, Inc. 10%+ Owner Series A Preferred Stock 0 11 May 2021 By Longitude Venture Partners III, L.P.
Talaris Therapeutics, Inc. 10%+ Owner Series B Preferred Stock 0 11 May 2021 By Longitude Venture Partners III, L.P.

Insider Reports Filed by Longitude Capital Partners III, LLC

Symbol Company Period Transactions Value $ Form Type Role Filing Time
/report/000089924322016052-longitude-capital-partners-iii-llc-2022-04-27 Sierra Oncology, Inc. 27 Apr 2022 8 $0 4 10%+ Owner 29 Apr 2022, 19:07
INZY Inozyme Pharma, Inc. 19 Apr 2022 1 +$4,999,950 4 10%+ Owner 21 Apr 2022, 18:04
/report/000089924322004271-longitude-capital-partners-iii-llc-2022-01-31 Sierra Oncology, Inc. 31 Jan 2022 1 +$4,725,000 4 10%+ Owner 02 Feb 2022, 20:25
/report/000089924322003502-longitude-capital-partners-iii-llc-2022-01-25 Sierra Oncology, Inc. 25 Jan 2022 2 -$13,063,697 4 10%+ Owner 27 Jan 2022, 20:23
TRML Talaris Therapeutics, Inc. 11 May 2021 5 +$3,995,000 4 10%+ Owner 11 May 2021, 20:29